Aura Biosciences, Inc. (AURA) Form 8-K — Nov 9, 2026
Aura Biosciences reported Q3 2026 results with a net loss of $32.1 million versus $26.1 million a year ago, and R&D expense of $24.7 million as its Phase 3 CoMpass trial of bel-sar progresses. The company holds $297.2 million in cash and marketable securities, which it says funds operations into the first half of 2029. It also incurred roughly $4.5 million in restructuring charges from a Q3 reorganization and established a new CDMO relationship with designated manufacturing capacity for bel-sar. The fully enrolled 108-participant Phase 3 CoMpass trial in early choroidal melanoma is on track for topline data in the second half of 2027 under an FDA Special Protocol Assessment.
Key figures
- Guidance
- Cash runway into the first half of 2029; Phase 3 CoMpass topline data expected 2H 2027
- Cash Position
- 297200000
- Q3 2025 net loss
- $26.1 million
- Phase3 enrollment
- 108
- Shares outstanding
- 103950771
- Marketable securities
- $255.6 million
- Restructuring charges
- $4.5 million
- Q3 2026 g and a expense
- $10.3 million vs $5.7 million year-ago
- Q3 2026 r and d expense
- $24.7 million vs $22.2 million year-ago
- Cash and cash equivalents
- $41.7 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.